1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20625
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorMakatsoris, T.en
dc.contributor.authorPapamichael, D.en
dc.contributor.authorVourli, G.en
dc.contributor.authorXanthakis, I.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorPapadimitriou, C.en
dc.contributor.authorPentheroudakis, G.en
dc.contributor.authorVarthalitis, I.en
dc.contributor.authorSamelis, G.en
dc.contributor.authorSyrigos, K. N.en
dc.contributor.authorXiros, N.en
dc.contributor.authorStavropoulos, M.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorChristodoulou, C.en
dc.contributor.authorLinardou, H.en
dc.contributor.authorSkondra, M.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorEconomopoulos, T.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:08:57Z-
dc.date.available2015-11-24T19:08:57Z-
dc.identifier.issn1791-7530-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20625-
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma/*drug therapyen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectCamptothecin/administration & dosage/adverse effects/analogs & derivativesen
dc.subjectColorectal Neoplasms/*drug therapyen
dc.subjectFemaleen
dc.subjectFluorouracil/administration & dosage/adverse effectsen
dc.subjectFollow-Up Studiesen
dc.subjectHumansen
dc.subjectLeucovorin/administration & dosage/adverse effectsen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectOrganoplatinum Compounds/administration & dosage/adverse effectsen
dc.titleIrinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal canceren
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/21036759-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2010-
heal.abstractBACKGROUND: This study reports the long-term follow-up of patients with metastatic colorectal cancer (CRC) participating in a randomised phase II study that compared the efficacy and toxicity of the combination of irinotecan (IRI), fluorouracil (FU) with leucovorin (LV) (arm A) versus sequential chemotherapy with IRI plus FU/LV followed by oxaliplatin (OXA) plus FU/LV (arm B) as first line therapy. MATERIALS AND METHODS: Intent-to-treat analysis was performed on 417 patients (211 in arm A and 206 in arm B). Treatment schedules of weekly IRI 80 mg/m(2) or OXA 45 mg/m(2) plus LV 200 mg/m(2) immediately followed by intravenous bolus FU 450 mg/m(2) for 6 weeks were followed by a 2-week rest period. Treatment continued for 4 cycles. Patients in arm A were treated with IRI/FU/LV for 4 cycles, while patients in arm B were initially treated with IRI/FU/LV for 2 cycles followed by sequential administration of 2 cycles of OXA/FU/LV. RESULTS: No significant difference emerged in overall response rate or overall survival. There was a difference in progression-free survival (median, 7.3 versus 8.2 months, p=0.040) in favour of arm B. Toxicity profiles were similar in both arms. CONCLUSION: IRI/FU/LV and IRI/FU/LV followed by OXA/FU/LV showed comparable activity with a manageable toxicity profile.en
heal.journalNameAnticancer Resen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons